Document Detail


Treatment of infantile hemangiomas with sirolimus in a patient with PHACE syndrome.
MedLine Citation:
PMID:  23316753     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Infantile hemangiomas (IHs) are common benign tumors of childhood. IHs often regress satisfactorily without intervention, but a subset of IHs may lead to functional or cosmetic morbidity necessitating therapy. PHACE syndrome is characterized by a variety of neurocutaneous and vascular anomalies that typically include segmental hemangiomas. We present an infant with PHACE syndrome and segmental IH that failed conventional first-line therapies. Treatment with sirolimus provided benefit with regression of the cutaneous IH. As an inhibitor of the mammalian target of rapamycin (mTOR) pathway, the effective use of sirolimus may shed light on the emerging role of mTOR signaling in the development and pathogenesis of IHs.
Authors:
Samer Kaylani; Amy J Theos; Joseph G Pressey
Related Documents :
23266923 - Initiation and use of propranolol for infantile hemangioma: report of a consensus confe...
24466713 - Fatal suicidal poisoning with antituberculosis agents with st elevation and acute coron...
24113443 - Association between multiple myeloma and acute myeloid leukemia secondary to myelodyspl...
Publication Detail:
Type:  Case Reports; Journal Article     Date:  2013-01-15
Journal Detail:
Title:  Pediatric dermatology     Volume:  30     ISSN:  1525-1470     ISO Abbreviation:  Pediatr Dermatol     Publication Date:    2013 Nov-Dec
Date Detail:
Created Date:  2013-11-28     Completed Date:  2014-08-18     Revised Date:  2014-11-18    
Medline Journal Info:
Nlm Unique ID:  8406799     Medline TA:  Pediatr Dermatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  e194-7     Citation Subset:  IM    
Copyright Information:
© 2013 Wiley Periodicals, Inc.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibiotics, Antineoplastic / therapeutic use
Aortic Coarctation / drug therapy*
Eye Abnormalities / drug therapy*
Facial Neoplasms / drug therapy*
Female
Hemangioma / drug therapy*
Humans
Infant, Newborn
Neurocutaneous Syndromes / drug therapy*
Sirolimus / therapeutic use*
Skin Neoplasms / drug therapy*
Chemical
Reg. No./Substance:
0/Antibiotics, Antineoplastic; W36ZG6FT64/Sirolimus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Mitochondrial genome of Protobothrops jerdonii (Squamata: Viperidae: Crotalinae).
Next Document:  Drink driving in Hong Kong: The competing effects of random breath testing and alcohol tax reduction...